Literature DB >> 19946118

Long-term effects of intracoronary bone marrow cell transfer on diastolic function in patients after acute myocardial infarction: 5-year results from the randomized-controlled BOOST trial--an echocardiographic study.

Arnd Schaefer1, Carolin Zwadlo, Martin Fuchs, Gerd P Meyer, Peter Lippolt, Kai C Wollert, Helmut Drexler.   

Abstract

AIMS: We have recently observed that intracoronary autologous bone marrow cell (BMC)-transfer improves parameters of diastolic function in patients after acute myocardial infarction at 6 and 18 months. There is no clinical study addressing the long-term effect of BMC transfer on diastolic function. Therefore, we conducted a 5-year follow-up of the BOOST trial to evaluate a sustained benefit on echocardiographic parameters on diastolic function. METHODS AND
RESULTS: After successful primary percutaneous coronary intervention (PCI) for acute ST-elevation MI, patients were randomized to a control (n = 28) or BMC transfer group (n = 28). Echocardiography was performed at 4.5 +/- 1.5 days after PCI, at 6, 18, and 60 months. Diastolic function was determined by measuring transmitral flow velocities (E/A ratio), diastolic myocardial velocities (E(a)/A(a) ratio), isovolumic relaxation time (IVRT), and deceleration time (DT). All analyses were performed in a blinded fashion. There was an overall treatment effect of BMC transfer on E/A (0.25 +/- 0.10; 95% CI 0.05-0.44; P = 0.01). E/A ratio was significantly lower at 6 (Control 0.90 +/- 0.07; BMC 1.23 +/- 0.14; P = 0.03) and 18 months (Control 0.87+/-0.04; BMC 1.13 +/- 0.09; P = 0.01) in the control group, whereas E/A ratio was not different at 60 months between both groups (Control 0.90 +/- 0.06; BMC 1.05 +/- 0.07; P = 0.12). We found no overall effect of BMC transfer on E(a)/A(a) ratio (0.21 +/- 0.14; 95% CI -0.03 to 0.46; P = 0.09), DT (-12 +/- 11 ms; 95% CI -21 to 28; P = 0.75), IVRT -6 +/- 7 ms; 95% CI -9 to 19; P = 0.43), and E/E(a) ratio (0.58 +/- 0.88; 95% CI -1.18 to 2.34; P = 0.51).
CONCLUSION: Intracoronary autologous BMC transfer provides an overall treatment effect on echocardiographic parameters of diastolic function in patients after AMI. However, this effect is basically related to an early improvement of parameters of diastolic function without a sustained effect on long-term follow-up.

Entities:  

Mesh:

Year:  2009        PMID: 19946118     DOI: 10.1093/ejechocard/jep191

Source DB:  PubMed          Journal:  Eur J Echocardiogr        ISSN: 1532-2114


  24 in total

Review 1.  Genetic engineering of mesenchymal stem cells and its application in human disease therapy.

Authors:  Conrad P Hodgkinson; José A Gomez; Maria Mirotsou; Victor J Dzau
Journal:  Hum Gene Ther       Date:  2010-10-22       Impact factor: 5.695

2.  Cardiac fibroblast-derived 3D extracellular matrix seeded with mesenchymal stem cells as a novel device to transfer cells to the ischemic myocardium.

Authors:  Eric G Schmuck; Jacob D Mulligan; Rebecca L Ertel; Nicholas A Kouris; Brenda M Ogle; Amish N Raval; Kurt W Saupe
Journal:  Cardiovasc Eng Technol       Date:  2014-03-01       Impact factor: 2.495

3.  Tracking stem cells for cardiovascular applications in vivo: focus on imaging techniques.

Authors:  Yingli Fu; Nicole Azene; Yi Xu; Dara L Kraitchman
Journal:  Imaging Med       Date:  2011-08-01

4.  Improved targeting and enhanced retention of the human, autologous, fibroblast-derived, induced, pluripotent stem cells to the sarcomeres of the infarcted myocardium with the aid of the bioengineered, heterospecific, tetravalent antibodies.

Authors:  Marek Malecki
Journal:  J Stem Cell Res Ther       Date:  2013-05-06

5.  Early remodeling processes as predictors of diastolic function 5 years after reperfused acute myocardial infarction and intracoronary progenitor cell application.

Authors:  Ulrich Fischer-Rasokat; Jörg Honold; Florian H Seeger; Stephan Fichtlscherer; Volker Schächinger; Stefanie Dimmeler; Andreas M Zeiher; Birgit Assmus
Journal:  Clin Res Cardiol       Date:  2011-11-22       Impact factor: 5.460

Review 6.  Imaging: guiding the clinical translation of cardiac stem cell therapy.

Authors:  Patricia K Nguyen; Feng Lan; Yongming Wang; Joseph C Wu
Journal:  Circ Res       Date:  2011-09-30       Impact factor: 17.367

Review 7.  Cell-based therapy for prevention and reversal of myocardial remodeling.

Authors:  Vasileios Karantalis; Wayne Balkan; Ivonne H Schulman; Konstantinos E Hatzistergos; Joshua M Hare
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-05-25       Impact factor: 4.733

Review 8.  Key developments in stem cell therapy in cardiology.

Authors:  Ivonne H Schulman; Joshua M Hare
Journal:  Regen Med       Date:  2012-11       Impact factor: 3.806

Review 9.  Mesenchymal stem cells for cardiac therapy: practical challenges and potential mechanisms.

Authors:  Timothy J Cashman; Valerie Gouon-Evans; Kevin D Costa
Journal:  Stem Cell Rev Rep       Date:  2013-06       Impact factor: 5.739

Review 10.  Mesenchymal stem cell-derived extracellular vesicles in the failing heart: past, present, and future.

Authors:  Catherine Karbasiafshar; Frank W Sellke; M Ruhul Abid
Journal:  Am J Physiol Heart Circ Physiol       Date:  2021-04-16       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.